Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

5.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.4K
Clinical Trials01:16

Clinical Trials

11.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.1K
Toxidromes: Clinical Features01:30

Toxidromes: Clinical Features

114
Toxidromes are specific patterns of symptoms resulting from toxic substance exposure. They help in the identification and treatment of poisoning. The symptoms of each toxidrome group indicate poisoning by a certain class of chemicals or drugs.1. Sympathomimetic: Stimulates the sympathetic nervous system. Symptoms include agitation, increased heart rate (HR), blood pressure (BP), respiratory rate (RR), temperature, and pupil size. Drugs like cocaine and amphetamines, along with tremors and...
114
Cytoplasm01:16

Cytoplasm

94.5K
The cytoplasm consists of organelles and a framework of protein scaffolds called the cytoskeleton suspended in an aqueous solution, the cytosol. The cytosol is a rich broth of water, ions, salts, and various organic molecules.
Protein Folding and Misfolding
The cytoplasm is the location for several cellular processes, including protein synthesis and folding. The aqueous nature of the cytosol promotes protein folding such that the hydrophobic amino acid side chains are buried in the protein...
94.5K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

612
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
612

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatic CYP1A2 Activity in Adolescents with and without Obesity Assessed by the Urinary Paraxanthine-to-Caffeine Metabolic Ratio: A Pharmacokinetic Study.

Journal of clinical pharmacology·2026
Same author

Medication concentrations in human milk and potential adverse effects in breastfed infants (MedMilk): a protocol for an observational clinical study.

BMJ open·2026
Same author

Genetic determinants of childhood blood pressure and heart rate in relation to adult health outcomes: the consortium of childhood blood pressure.

European heart journal·2026
Same author

Colour of medicines and children's acceptability: What children think of the colour of oral dosage forms?

Frontiers in drug delivery·2026
Same author

Patients' Attitudes Towards Deprescribing and Associations With Patient-Related Factors Across Two Hospital Settings.

Basic & clinical pharmacology & toxicology·2026
Same author

Lack of formal regulatory definitions of off-label medication use in children: an analysis using agency inquiry and text mining.

Frontiers in pharmacology·2026
Same journal

Translation of the Breathing Vigilance Questionnaire for respiratory diseases.

Danish medical journal·2026
Same journal

Consensus on key concepts in audiometry.

Danish medical journal·2026
Same journal

Translation and validation of the Lee Chronic Graft-versus-Host Disease Symptom Scale in Denmark.

Danish medical journal·2026
Same journal

Variation in microbiological test requisitions among general practices in the North Denmark Region.

Danish medical journal·2026
Same journal

Diagnostic accuracy of common infectious disease discharge diagnoses from emergency department.

Danish medical journal·2026
Same journal

Minimally invasive ventral mesh rectopexy.

Danish medical journal·2026
See all related articles

Related Experiment Video

Updated: Mar 22, 2026

ExCYT: A Graphical User Interface for Streamlining Analysis of High-Dimensional Cytometry Data
05:12

ExCYT: A Graphical User Interface for Streamlining Analysis of High-Dimensional Cytometry Data

Published on: January 16, 2019

12.0K

The CYTONOX trial.

Christina Gade1, Gerd Mikus, Hanne Rolighed Christensen

  • 1christina.gade@regionh.dk.

Danish Medical Journal
|April 30, 2016
PubMed
Summary
This summary is machine-generated.

This study investigates how obesity affects drug metabolism in children. Understanding these changes in cytochrome P450 enzyme activity is crucial for safe and effective medication dosing in pediatric obesity.

More Related Videos

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.3K
Non-invasive Strategies for Chronic Manipulation of DREADD-controlled Neuronal Activity
08:28

Non-invasive Strategies for Chronic Manipulation of DREADD-controlled Neuronal Activity

Published on: August 25, 2019

14.6K

Related Experiment Videos

Last Updated: Mar 22, 2026

ExCYT: A Graphical User Interface for Streamlining Analysis of High-Dimensional Cytometry Data
05:12

ExCYT: A Graphical User Interface for Streamlining Analysis of High-Dimensional Cytometry Data

Published on: January 16, 2019

12.0K
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.3K
Non-invasive Strategies for Chronic Manipulation of DREADD-controlled Neuronal Activity
08:28

Non-invasive Strategies for Chronic Manipulation of DREADD-controlled Neuronal Activity

Published on: August 25, 2019

14.6K

Area of Science:

  • Pharmacokinetics and Drug Metabolism
  • Pediatric Endocrinology
  • Clinical Pharmacology

Background:

  • Childhood obesity affects 3-5% of Danish children, with potential impacts on drug pharmacokinetics.
  • Obesity in adults alters drug-metabolizing enzyme pathways, but effects in children are largely unknown.
  • Altered drug metabolism in obese children may lead to therapeutic failure or toxicity.

Purpose of the Study:

  • To investigate the in vivo activity of key drug-metabolizing enzymes (CYP3A4, CYP2E1, CYP1A2) in obese versus non-obese children.
  • To establish a basis for future drug dosing recommendations in pediatric obesity.

Main Methods:

  • The CYTONOX trial is an open-label, exploratory pharmacokinetic study.
  • 50 obese and 50 non-obese children will be included.
  • In vivo clearance of CYP3A4, CYP2E1, and CYP1A2 substrates (midazolam, chlorzoxazone, caffeine) will be measured via single-dose administration and sample collection.

Main Results:

  • Data collection and analysis are ongoing.
  • Results will elucidate the impact of obesity on specific drug-metabolizing enzyme activity in children.

Conclusions:

  • The CYTONOX trial aims to determine in vivo activity of CYP3A4, CYP2E1, and CYP1A2 in obese vs. non-obese children.
  • Findings are expected to inform future drug dosing guidelines for obese children.